Clinical Cancer Research Bridging the Lab and the Clinic in Cancer Medicine Infection and Cancer: Biology, Therapeutics, and Prevention
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Zhang, F.
Right arrow Articles by Dong, Z.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Zhang, F.
Right arrow Articles by Dong, Z.
Clinical Cancer Research Vol. 11, 4512-4520, June 15, 2005
© 2005 American Association for Cancer Research


Cancer Therapy: Preclinical

Blockade of Transforming Growth Factor-ß Signaling Suppresses Progression of Androgen-Independent Human Prostate Cancer in Nude Mice

Fahao Zhang2, Juwon Lee1, Shan Lu1, Curtis A. Pettaway2 and Zhongyun Dong1

Authors' Affiliations: 1 Department of Internal Medicine, University of Cincinnati College of Medicine, Cincinnati, Ohio and 2 Department of Cancer Biology, University of Texas M.D. Anderson Cancer Center, Houston, Texas

Requests for reprints: Zhongyun Dong, Department of Internal Medicine, Hematology-Oncology Division, Box 0508, University of Cincinnati College of Medicine, Room 1308, 3125 Eden Avenue, Cincinnati, OH 45267. Phone: 513-558-2176; Fax: 513-558-6703; E-mail: dongzu{at}ucmail.uc.edu.

We investigated the role of transforming growth factor-ß (TGF-ß) signaling in the growth and metastasis of PC-3MM2 human prostate cancer cells. Highly metastatic PC-3MM2 human prostate cancer cells were engineered to constitutively overexpress a dominant-negative type II TGF-ß receptor (DNR). Transfection of DNR had minimal direct effects on cell growth and attenuated TGF-ß-induced cell growth inhibition and TGF-ß1 production. There were no discernable differences in tumorigenicity (tumor incidence) among PC-3MM2 variants when the cells were implanted into the prostates of nude mice. Growth rate and metastatic incidence of DNR-engineered PC-3MM2 cells, however, were significantly reduced. Most cells in the control tumors were positively stained by an antibody to proliferation cell nuclear antigen and very few cells were stained by terminal deoxynucleotidyl transferase–mediated nick-end labeling (TUNEL). In sharp contrast, tumors formed by PC-3MM2-DNR cells contained fewer proliferation cell nuclear antigen–positive cells and many more TUNEL-positive cells. Staining with antibody against CD31 showed that control tumors contained more blood vessels than PC-3MM2-DNR tumors. Expression of interleukin-8 (IL-8) in tumors formed by PC-3MM2 cells was significantly reduced as revealed by both Northern blotting and ELISA. Finally, transfection of antisense IL-8 cDNA significantly reduced IL-8 production by PC-3MM2 cells and antisense IL-8-transfected PC-3MM2 cells grew slower in comparison with parental and control vector-transfected cells. Taken together, our data suggest that TGF-ß signaling, by regulating IL-8 expression in tumor cells and hence tumor angiogenesis, is critical for progressive growth of PC-3MM2 cells in the prostate of nude mice.

Key Words: TGF-ß • Receptor • prostate cancer • angiogenesis • IL-8




This article has been cited by other articles:


Home page
J. Immunol.Home page
M. Zhang, B. E. Berndt, J.-J. Chen, and J. Y. Kao
Expression of a Soluble TGF-{beta} Receptor by Tumor Cells Enhances Dendritic Cell/Tumor Fusion Vaccine Efficacy
J. Immunol., September 1, 2008; 181(5): 3690 - 3697.
[Abstract] [Full Text] [PDF]


Home page
Protein Eng Des SelHome page
E. V. Verona, Y. Tang, T. K. Millstead, A. P. Hinck, J. K. Agyin, and L.-Z. Sun
Expression, purification and characterization of BGERII: a novel pan-TGF{beta} inhibitor
Protein Eng. Des. Sel., July 1, 2008; 21(7): 463 - 473.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
S. Lu, J. Lee, M. Revelo, X. Wang, S. Lu, and Z. Dong
Smad3 Is Overexpressed in Advanced Human Prostate Cancer and Necessary for Progressive Growth of Prostate Cancer Cells in Nude Mice
Clin. Cancer Res., October 1, 2007; 13(19): 5692 - 5702.
[Abstract] [Full Text] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
S. Lu, A. Wang, S. Lu, and Z. Dong
A novel synthetic compound that interrupts androgen receptor signaling in human prostate cancer cells
Mol. Cancer Ther., July 1, 2007; 6(7): 2057 - 2064.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
R. Ge, V. Rajeev, P. Ray, E. Lattime, S. Rittling, S. Medicherla, A. Protter, A. Murphy, J. Chakravarty, S. Dugar, et al.
Inhibition of Growth and Metastasis of Mouse Mammary Carcinoma by Selective Inhibitor of Transforming Growth Factor-{beta} Type I Receptor Kinase In vivo.
Clin. Cancer Res., July 15, 2006; 12(14): 4315 - 4330.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2005 by the American Association for Cancer Research.